Related Experiment Videos
Advanced glycation end products and endothelial dysfunction in type 2 diabetes
Kathryn C B Tan1, Wing-Sun Chow, Victor H G Ai
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Honk Kong. kcbtan@hkucc.hku.hk
Diabetes Care
|May 29, 2002
Summary
High serum levels of advanced glycation end products (AGEs) are linked to endothelial dysfunction in type 2 diabetes patients. This indicates AGEs may be a key factor in diabetes-related vascular complications.
Area of Science:
- Endocrinology
- Vascular Biology
- Metabolic Diseases
Background:
- Advanced glycation end products (AGEs) are implicated in diabetes complications.
- Endothelial dysfunction is a hallmark of diabetes, contributing to cardiovascular risk.
Purpose of the Study:
- To investigate the relationship between serum AGEs concentrations and endothelial function in type 2 diabetes.
- To assess if serum AGEs are an independent predictor of endothelial dysfunction.
Main Methods:
- 170 type 2 diabetes patients and 83 controls were recruited.
- Serum AGEs measured by ELISA; vasodilation assessed by ultrasound.
- Endothelium-dependent and -independent vasodilation evaluated.
Main Results:
- Diabetic patients had higher serum AGEs and impaired vasodilation.
- Serum AGEs strongly correlated with reduced endothelium-dependent vasodilation (r = -0.51).
- Serum AGEs were an independent determinant of endothelial dysfunction.
Conclusions:
- Elevated serum AGEs are associated with endothelial dysfunction in type 2 diabetes.
- This association is independent of other cardiovascular risk factors.
- Targeting AGEs may be a therapeutic strategy for diabetic vascular complications.